Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-15 | Dec-31-14 | Dec-31-13 |
| | 10-K | 10-K | 10-K |
| Revenues |
| Hemophilia | 2,840 | 2,984 | 2,786 |
| Immunoglobulin Therapies | 1,750 | 1,677 | 1,616 |
| Inhibitor Therapies | 787 | 744 | 651 |
| Bio Therapeutics | 684 | 547 | 502 |
| Oncology | 87 | | |
| |
| Mix |
| Hemophilia | 46.2% | 50.1% | 50.2% |
| Immunoglobulin Therapies | 28.5% | 28.2% | 29.1% |
| Inhibitor Therapies | 12.8% | 12.5% | 11.7% |
| Bio Therapeutics | 11.1% | 9.2% | 9.0% |
| Oncology | 1.4% | | |
| |
| Growth |
| Hemophilia | -4.8% | 7.1% | |
| Immunoglobulin Therapies | 4.4% | 3.8% | |
| Inhibitor Therapies | 5.8% | 14.3% | |
| Bio Therapeutics | 25.0% | 9.0% | |
|